| Literature DB >> 34267786 |
André Brusamolin Moro1, João Gabriel Nakka Strauch2, Anderson Dillmann Groto3, Jeferson Freitas Toregeani1,4.
Abstract
Variation in the creatinine levels of patients who have undergone contrast-enhanced computed tomography (CT) has been adopted as a practical method for assessment of possible kidney damage caused by the contrast. Criteria employed include an absolute increase in serum creatinine ≥ 0.5 mg/dL or a relative increase ≥ 25% as indicative of possible renal disorders, such as contrast-induced nephropathy (CIN). Our objective was to analyze the incidence of CIN by means of a meta-analysis of nine articles related to incidence of kidney damage caused by contrast, calculating odds ratios (OR) and confidence intervals (95%CI) using RStudio. The overall incidence of CIN in patients who had CT scans was 11.29%, with an OR of 1.38 (95%CI 0.88-2.16). Non-ionic contrasts are safer than other types of contrast, and volumes exceeding 115 mL may be associated with CIN. Preexisting kidney disease had a statistically significant relationship with worse CIN rates. CopyrightEntities:
Keywords: contrast media; kidney diseases; tomography
Year: 2021 PMID: 34267786 PMCID: PMC8256998 DOI: 10.1590/1677-5449.200161
Source DB: PubMed Journal: J Vasc Bras ISSN: 1677-5449
Description of contrast media.
|
|
|
|
|
|---|---|---|---|
| Ionic monomer |
| High osmolality | Metrizoate (Isopaque®) |
| Ionic dimer |
| Low osmolality | Ioxaglate meglumine (Hexabrix®) |
| Non-ionic monomer |
| Low osmolality | Iohexol (Ominipaque ®) |
| Iomeprol (Iomeron®) | |||
| Iopromide (Ultravist®) | |||
| Iopamidol (Isovue®) | |||
| Non-ionic dimer |
| Iso-osmolality | Iodixanol (Visipaque®) |
Figure 1Flow diagram.
Figure 2Forest plot. OBS: Hemmett et al.,21 – the first phase of the study was conducted from December 1 to December 12, 2012; Hemmett et al.,21 – the second phase of the study was conducted from October 1 to October 13, 2013.
Methods used to conduct contrast-enhanced tomography.
|
|
|
|
|
|
|---|---|---|---|---|
| Hinson et al. | Unspecified contrast-enhanced CT | Non-ionic – | From 80 to 120 mL | 2B |
| iohexol and iodixanol | ||||
| McDonald et. | Contrast-enhanced CT of abdomen, pelvis, and thorax | Non-ionic – | From 80 to 200 mL | 2B |
| iohexol and iodixanol | ||||
| Heller et al. | Unspecified contrast-enhanced CT | Non-ionic – | 100 mL | 2B |
| iohexol and iopamidol | ||||
| Murakami et al. | Contrast-enhanced multi-detector CT (MDCT) of brain, neck, abdomen, pelvis and thorax | Non-ionic – | 1 to 2 mL/kg up to a maximum of 150 mL, via infusion pump | 2B |
| iohexol, iopamidol, iopromide, iomeprol | ||||
| Puchol et al. | Unspecified contrast-enhanced multi-detector CT (MDCT) | Unspecified low osmolar contrast | From 50 to 200 mL | 2B |
| Hemmett et al. | Contrast-enhanced CT of the brain, spine, abdomen, pelvis, and thorax | – | – | 2B |
| McDonald et. | Contrast-enhanced CT of the abdomen, pelvis, and thorax | – | – | 2B |
| Peer et al. | Unspecified contrast-enhanced CT | Unspecified low osmolar and iso-osmolar contrast | Mean of 115.71 mL in patients with CIN and mean of 76.15 mL in patients without CIN | 2B |
| Sonhaye et al. | Contrast-enhanced CT of the brain, abdomen and thorax | Non-ionic – | 1.5 mL/kg up to a maximum of 150 mL | 2B |
| iomeprol |
McDonald et al.22 and Hemmett et al.21 did not report the contrast used or the volume administered.
Descrição dos meios de contraste.
|
|
|
|
|
|---|---|---|---|
| Monômero iônico |
| Hiperosmolar | Metrizoato (Isopaque®) |
| Dímero iônico |
| Hiposmolar | Ioxaglato de meglumina (Hexabrix®) |
| Monômero não iônico |
| Hiposmolar | Iohexol (Ominipaque ®) |
| Iomeprol (Iomeron®) | |||
| Iopromida (Ultravist®) | |||
| Iopamidol (Isovue®) | |||
| Dímero não iônico |
| Isosmolar | Iodixanol (Visipaque®) |
Figura 1Fluxograma.
Figura 2Forest plot. OBS: Hemmett et al.21, – a primeira fase desse estudo foi realizada entre os dias 1 e 12 de dezembro de 2012; Hemmett et al.21, – a segunda fase desse estudo foi realizada entre os dias 1 e 13 de outubro de 2013.
Métodos utilizados para a realização da tomografia contrastada.
|
|
|
|
|
|
|---|---|---|---|---|
| Hinson et al. | TC contrastada não especificada | Não iônico – | Entre 80 e 120 mL | 2B |
| iohexol e iodixanol | ||||
| McDonald et. | TC contrastada de abdome, pelve e tórax | Não iônico – | Entre 80 e 200 mL | 2B |
| iohexol e iodixanol | ||||
| Heller et al. | TC contrastada não especificada | Não iônico – | 100 mL | 2B |
| iohexol e iopamidol | ||||
| Murakami et al. | TC multidetectora (MDCT) Contrastada de cérebro, pescoço, abdome, pelve e tórax | Não iônico – | 1 a 2 mL/kg até no máximo 150 mL por bomba de infusão | 2B |
| iohexol, iopamidol, iopromida, iomeprol | ||||
| Puchol et al. | TC multidetectora (MDCT) Contrastada não especificada | Contraste hiposmolar não especificado | Entre 50 e 200 mL | 2B |
| Hemmett et al. | TC contrastada de cérebro, coluna, abdome, pelve e tórax | – | – | 2B |
| McDonald et. | TC contrastada de abdome, pelve e tórax | – | – | 2B |
| Peer et al. | TC contrastada não especificada | Contraste hiposmolar e isosmolar não especificado | Média de 115,71 mL nos pacientes com NIC e média de 76,15 mL nos pacientes sem NIC | 2B |
| Sonhaye et al. | TC contrastada de cérebro, abdome e tórax | Não iônico – | 1,5 mL/kg até no máximo 150 mL | 2B |
| iomeprol |
McDonald et al.22 e Hemmett et al.21 não descreveram o contraste utilizado e o volume administrado.